By Lina carolina 
The global landscape of cancer is undergoing a dramatic and alarming transformation, with new diagnoses and fatalities escalating at unprecedented rates. A comprehensive analysis, published in the prestigious journal The Lancet, reveals that the number of new cancer cases worldwide has more than doubled since 1990, reaching an estimated 18.5 million in 2023. Over the same period, annual cancer deaths have surged by a staggering 74 percent, claiming 10.4 million lives. This escalating crisis disproportionately impacts individuals in low- and middle-income countries (LMICs), where access to essential healthcare services remains a significant challenge.
The Accelerating Global Burden of Cancer
The findings underscore a profound shift in the global health agenda. The sheer volume of new cancer diagnoses, excluding non-melanoma skin cancers, has climbed from approximately 9 million in 1990 to the current 18.5 million. This represents an increase of over 100 percent in just over three decades. Correspondingly, the death toll has risen from around 5.9 million in 1990 to 10.4 million in 2023, a substantial 74 percent increase.
Crucially, this growing burden is not uniformly distributed. While high-income nations have seen some progress in reducing age-adjusted cancer death rates, LMICs are grappling with both an increasing number of cases and rising mortality rates. This disparity highlights deep-seated inequities in healthcare systems and access to vital medical resources.
A Look Ahead: Projections Signal a Looming Crisis
The outlook for the coming decades is equally concerning. Researchers project that new cancer cases will continue their upward trajectory, with an estimated 61 percent increase expected over the next 25 years. By 2050, the global toll could reach 30.5 million new diagnoses annually. Cancer deaths are forecast to mirror this grim trend, with a nearly 75 percent rise anticipated, bringing the annual mortality figure to 18.6 million.
These projections are largely attributed to two significant demographic shifts: population growth and the increasing aging of the global population. As more people live longer lives, the cumulative risk of developing cancer naturally increases. However, the analysis also points to the role of modifiable risk factors in exacerbating this trend.
The Preventable Face of Cancer: A Call for Action
A particularly sobering aspect of the study is the revelation that more than 40 percent of all cancer deaths worldwide are linked to 44 identifiable and modifiable risk factors. This statistic offers a crucial glimmer of hope, suggesting that a substantial proportion of these tragic outcomes could be averted through targeted prevention strategies. Among the most significant culprits identified are tobacco use, poor dietary habits, and high blood sugar levels, all of which are amenable to public health interventions and individual lifestyle changes.
This finding strongly suggests that robust investment in cancer prevention programs, alongside efforts to improve early detection and ensure universal access to quality treatment, could dramatically alter the trajectory of this global health crisis.
Uneven Progress and Deepening Disparities
Despite advancements in cancer treatment and a growing awareness of risk factors, the overall global age-adjusted cancer death rate has seen a decline of 24 percent between 1990 and 2023. However, this progress is far from equitable. The study reveals that this decline has been predominantly observed in high- and upper-middle-income countries. In stark contrast, low- and lower-middle-income countries have experienced increases in age-standardized cancer incidence rates – 24 percent and 29 percent respectively – indicating a worsening situation in regions with fewer resources to combat the disease.
Geographically, the analysis highlights significant regional variations. Lebanon, for instance, recorded the largest percentage increase in age-standardized cancer incidence and mortality rates for both sexes combined between 1990 and 2023. Conversely, the United Arab Emirates saw the greatest decline in age-standardized incidence, while Kazakhstan reported the largest decrease in age-standardized death rates over the same period.
In terms of specific cancer types, breast cancer emerged as the most commonly diagnosed cancer globally in 2023, affecting both sexes combined. Tracheal, bronchus, and lung (TBL) cancer, however, remained the leading cause of cancer-related deaths worldwide.
Identifying and Addressing Key Risk Factors
The study meticulously details the contribution of various modifiable risk factors to the global cancer burden. In 2023, an estimated 4.3 million out of the 10.4 million cancer deaths were attributable to 44 modifiable risk factors. Behavioral factors, in particular, accounted for a substantial share of these deaths across all income levels.
Tobacco use stands out as the single largest contributor, responsible for 21 percent of all cancer deaths globally. It was the leading risk factor in all income groups except for low-income countries, where unsafe sexual practices were identified as the primary risk factor, linked to 12.5 percent of cancer deaths.
Analysis also revealed gender-specific patterns. Men were found to be more susceptible to deaths from cancers linked to modifiable risks, with 46 percent of male cancer deaths in 2023 attributed to factors such as tobacco use, unhealthy diets, excessive alcohol consumption, occupational hazards, and air pollution. Among women, 36 percent of cancer deaths were associated with modifiable risks, with tobacco, unsafe sex, poor diet, obesity, and high blood sugar being the most significant contributors.
Expert Calls for a Renewed Global Commitment
Lead author Dr. Lisa Force from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington emphasized the urgency of the situation. "Cancer remains an important contributor to disease burden globally, and our study highlights how it is anticipated to grow substantially over the coming decades, with disproportionate growth in countries with limited resources," Dr. Force stated. "Despite the clear need for action, cancer control policies and implementation remain underprioritized in global health, and there is insufficient funding to address this challenge in many settings."
Dr. Force further stressed the critical need for equitable access to healthcare. "Ensuring equitable cancer outcomes globally will require greater efforts to reduce disparities in health service delivery, such as access to accurate and timely diagnosis, and quality treatment and supportive care."
Co-author Dr. Theo Vos, also from IHME, echoed these sentiments, pointing to the significant potential for prevention. "With four in 10 cancer deaths linked to established risk factors, including tobacco, poor diet, and high blood sugar, there are tremendous opportunities for countries to target these risk factors, potentially preventing cases of cancer and saving lives, alongside improving accurate and early diagnosis and treatment to support individuals who develop cancer," Dr. Vos remarked. "Reducing the burden of cancer across countries and worldwide demands both individual action and effective population-level approaches to reduce exposure to known risks."
The Path Forward: Prevention, Equity, and Data
The researchers are unequivocal in their call for cancer prevention to be integrated into health policies, particularly in LMICs. They argue that equitable cancer control efforts are paramount to ensuring that all patients receive timely and effective care, irrespective of their geographical location or socioeconomic status.
Dr. Meghnath Dhimal from the Nepal Health Research Council, a co-author, described the rising cancer burden in LMICs as an "impending disaster." He highlighted the existence of cost-effective interventions and urged for an interdisciplinary approach, multi-sectoral collaboration, and coordinated implementation to tackle the escalating non-communicable disease crisis in these regions.
The study’s findings are intended to serve as a critical tool for policymakers and global health organizations. "These new estimates and forecasts can support governments and the global health community in developing data-informed policies and actions to improve cancer control and outcomes around the world," Dr. Force explained. "They can also support tracking of progress towards global and regional cancer targets."
Furthermore, the analysis underscores a critical data gap. "Our analysis also highlights the need for more data from sources such as cancer and vital registries, particularly in lower resource settings," Dr. Force added. "Supporting cancer surveillance systems is crucial to informing both a local and global understanding of cancer burden."
Study Methodology and Limitations
The comprehensive analysis, conducted by the GBD 2023 Cancer Collaborators, drew upon a vast array of data sources. These included population-based cancer registries, vital registration systems, and interviews with family members or caregivers of individuals who had succumbed to cancer. The study provided updated global, regional, and national estimates for the period spanning 1990 to 2023, covering 204 countries and territories. It examined 47 different cancer types or groupings and 44 attributable risk factors. The projections extended through 2050, and the study also assessed progress towards the United Nations Sustainable Development Goal (SDG) of reducing premature deaths from non-communicable diseases by one-third by 2030.
However, the authors acknowledge certain limitations. The estimates are based on the best available data, but gaps in high-quality cancer data, especially in resource-limited countries, may affect precision. Additionally, the current estimates do not account for the impact of certain infectious diseases known to increase cancer risk in some lower-income regions, such as Helicobacter Pylori and Schistosoma haematobium. This omission could lead to an underestimation of cancer deaths linked to modifiable risks. The projections also do not factor in the potential long-term effects of the COVID-19 pandemic, recent global conflicts, or future medical breakthroughs that could significantly influence cancer trends.
A Global Call for Decisive Action
In a related commentary, Dr. Qingwei Luo and Dr. David P Smith from The University of Sydney and Cancer Council NSW, who were not involved in the study, emphasized the imperative for immediate and concerted action. "To ensure meaningful progress in reducing the global cancer burden, it is imperative that governments prioritize funding, strengthen health systems, reduce inequalities, and invest in robust cancer control initiatives and research on prevention, intervention, and implementation," they wrote. "Because the future of cancer control depends on decisive, collective action today."
The study was made possible through funding from the Gates Foundation, St Jude Children’s Research Hospital, and the St Baldrick’s Foundation. The findings serve as a stark warning and a powerful call to action for governments, healthcare providers, and individuals worldwide to confront the escalating cancer crisis with renewed commitment and coordinated efforts.
